Singapore-based Nanyang Biologics (NYB) and Delaware-headquartered Precisya Global Inc (PGI) have announced a strategic alliance that aims to revolutionize precision medicine by combining AI-powered natural compound discovery with advanced genetic risk profiling technologies.
The partnership, announced on May 10, 2025, will integrate genomic analysis with natural compound research to expedite the development of plant-based treatments specifically targeted at genetic conditions. This collaboration represents a significant step toward personalized medicine derived from natural sources.
Bridging AI and Genomics for Natural Therapeutics
At the core of this initiative is NYB's proprietary DTIGN (Drug-Target Interaction Graph Neural Network) platform, which has demonstrated a 27.03% improvement in prediction accuracy compared to leading benchmarks. The AI model will screen NYB's extensive library of plant-based compounds, significantly enhancing the identification of active compounds while shortening early-stage discovery timelines.
PGI will complement these capabilities by providing secure access to anonymized patient genomic data and advanced bioinformatic analysis. The company utilizes specialized genetic knowledge derived from over 22 million scientific publications to identify disease-relevant biomarkers and analyze correlations between natural compound responses and specific genetic variants.
"This collaboration represents a significant advancement in precision medicine," said Roland Ong, Founder and Chairman of Nanyang Biologics. "By combining our natural compound expertise and DTIGN technology with PGI's genomic capabilities, we aim to develop more targeted and effective treatments while significantly reducing the time and cost typically associated with drug discovery."
Comprehensive Validation Pathway
The strategic alliance has outlined a clear validation roadmap for potential therapeutic compounds. In the coming months, NYB and PGI will begin preclinical validation leveraging biobank data and molecular docking simulations, followed by rigorous in vitro and in vivo testing.
This integrated approach ensures robust scientific validation while maintaining high standards for efficacy and safety. The partnership will utilize joint biobanks and patient samples to support these comprehensive validation efforts.
Potential Impact on Healthcare
For patients with genetically predisposed chronic diseases, this collaboration could enable earlier interventions, improved outcomes, and personalized treatments derived from natural sources with scientific backing. The initiative promises several key advantages:
- Enhanced therapeutic efficacy through precisely targeted natural interventions
- Reduced adverse effects compared to conventional treatments
- Cost-effective solutions for individuals with genetic predispositions
- Earlier intervention opportunities for those with genetic risk factors
Beyond direct patient benefits, the partnership also paves the way for co-branded, gene-informed ingredient formulations targeting health-conscious consumers and medical professionals. This represents a paradigm shift from generalized treatments toward precision-first design powered by AI and genomics.
About the Companies
Precisya Global Inc. is a leading deep health tech company that maps genetic interference patterns across whole-body metabolic pathways, identifying causative and associative factors of chronic disease expressions. Through its state-of-the-art technology platform and comprehensive genomic database, PGI delivers precise, data-driven insights that enable personalized healthcare solutions and accelerate plant-based compound drug development processes.
Nanyang Biologics specializes in natural compound research and has developed one of the world's largest natural compound libraries. The company's proprietary DTIGN technology unlocks novel therapeutic opportunities with exceptional precision and speed, positioning NYB at the forefront of AI-driven natural product discovery.
